Drug Details
General Information of the Drug (ID: DR6516) | ||||
---|---|---|---|---|
Name |
Temozolomide
|
|||
Synonyms |
Methazolastone; Temodal; Temodar; Temozolamide; Temozolodida; Temozolomidum; Essex brand of temozolomide; Scheringbrand of temozolomide; Temozolodida [Spanish]; Temozolomidum [Latin]; M B 39831; MB 39831; Sch 52365; M & B 39831; M&B 39831; M-39831; Sch-52365; Schering-Plough brand of temozolomide; TMZ-Bioshuttle; Temodal (TN); Temodar (TN); Temozolomide [INN:BAN]; M&B-39831; Temozolomide (JAN/USAN/INN); 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; TMZ
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Brain cancer [ICD-11: 2A00] | Approved | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C6H6N6O2
|
|||
PubChem CID | ||||
Canonical SMILES |
CN1C(=O)N2C=NC(=C2N=N1)C(=O)N
|
|||
InChI |
1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)
|
|||
InChIKey |
BPEGJWRSRHCHSN-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 85622-93-1
|
|||
GDSC | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Beta asarone | Acorus tatarinowii | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | ||
Experimental
Result(s) |
Beta-asarone could promote the entry of TMZ into U252 cells through the membrane. | |||||
Biochanin A | Dalbergia volubilis | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | TP53 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
T98G | CVCL_0556 | Glioblastoma | Homo sapiens | |||
Experimental
Result(s) |
Biochanin A significantly enhanced the anticancer efficacy of temozolomide in GBM cells. | |||||
Borneol | Chrysanthemum x morifolium | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Phosphorylation | ATM | Molecule Info |
Pathway MAP
|
|
Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Activity | CASP7 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Activity | CASP9 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | FRP1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | TP53 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | ||
In-vivo Model | U251 cell suspension (1*109 cells) was inoculated in the armpit of 6-week-old Balb/c nude mice. | |||||
Experimental
Result(s) |
Natural borneol enhances temozolomide-induced anticancer efficiency against human glioma by triggering mitochondrial dysfunction and reactive oxide species-mediated oxidative damage. | |||||
Carnosic acid | Salvia rosmarinus | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | ||
LN-229 | CVCL_0393 | Glioblastoma | Homo sapiens | |||
Experimental
Result(s) |
Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma. | |||||
Celastrol | Celastrus strigillosus | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | NFKBIA | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | SK-MEL-19 | CVCL_6025 | Cutaneous melanoma | Homo sapiens | ||
SK-MEL-100 | CVCL_6067 | Cutaneous melanoma | Homo sapiens | |||
SK-MEL-173 | CVCL_6090 | Melanoma | Homo sapiens | |||
SK-MEL-192 | CVCL_6101 | Melanoma | Homo sapiens | |||
Experimental
Result(s) |
Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Celastrol treatment increased the levels of ubiquitinated proteins, reduced the levels of tumor necrosis factor-alpha-induced IkappaB phosphorylation, and blocked NF-kappaB translocation to the nucleus. | |||||
Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [7] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Induction | ROS generation | ||||
In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
Experimental
Result(s) |
Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling. | |||||
Delta-9-tetrahydrocannabinol | Cannabis sativa | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [8] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
T98G | CVCL_0556 | Glioblastoma | Homo sapiens | |||
HG19 cells isolated from brain tumor biopsies | Brain tumor | Homo sapiens | ||||
In-vivo Model | Tumors were induced in nude mice by subcutaneous injection of 5 * 106 U87 cells or 10 *106 T98 cells in PBS supplemented with 0.1% glucose. | |||||
Experimental
Result(s) |
The combined administration of Delta(9)-Tetrahydrocannabinol and temozolomide exerts a strong antitumoral action in glioma xenografts, an effect that is also observed in tumors that are resistant to TMZ treatment. | |||||
Elemene | Pogostemon cablin | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [9] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Phosphorylation | ATM | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | ERK1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | H2AFX | Molecule Info |
Pathway MAP
|
||
In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
T98G | CVCL_0556 | Glioblastoma | Homo sapiens | |||
U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | |||
LN-229 | CVCL_0393 | Glioblastoma | Homo sapiens | |||
C6 | CVCL_0194 | Rat malignant glioma | Rattus norvegicus | |||
Experimental
Result(s) |
Beta-elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway. | |||||
Ellagic acid | Lagerstroemia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [10] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | CDH2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
In-vitro Model | C6 | CVCL_0194 | Rat malignant glioma | Rattus norvegicus | ||
Experimental
Result(s) |
Combining ellagic acid with temozolomide mediates the cadherin switch and angiogenesis in a glioblastoma model. | |||||
Epigallocatechin gallate | Hamamelis virginiana | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [11] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | HSPA5 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | |||
LN-229 | CVCL_0393 | Glioblastoma | Homo sapiens | |||
In-vivo Model | 2*105 cells (U87 and U251) in a volume of 10L were injected into the right frontal lobe of the brain and thereafter the skin incision was sutured with silk thread in athymic mice. | |||||
Experimental
Result(s) |
Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. | |||||
Honokiol | Magnolia officinalis | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [12] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
GL261 | CVCL_Y003 | Mouse glioblastoma | Mus musculus | |||
Experimental
Result(s) |
Honokiol enhanced temozolomide-induced autophagy and apoptosis in drug-sensitive and -tolerant glioma cells. | |||||
Monocyte activating polypeptide II | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [13] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
|
In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | |||
In-vivo Model | Mice were implanted subcutaneously with GSCs or GSCs stably transfected with pre-miR-590-3p into the right flank regions of mice at 2 * 106 cells density. | |||||
Experimental
Result(s) |
EMAP-II in combination with TMZ suppresse malignant biological behaviors of GSCs via miR-590-3p/MACC1 inhibiting PI3K/AKT/mTOR signaling pathway, and might provide potential therapeutic approaches for human GSCs. | |||||
Noscapine | Papaver somniferum | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [14] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | U87/DK | CVCL_3428 | Glioblastoma | Homo sapiens | ||
In-vivo Model | For a xenograft model, 4*106 U87MG cells were inoculated subcutaneously into one flank of 5-6 weeks old, female nude mice. | |||||
Experimental
Result(s) |
NOS synergistically potentiated the efficacy of FDA-approved anti-cancer drugs against human glioblastoma cells, thereby allowing them to be used at lower doses and hence minimizing their toxic side effects. | |||||
Paclitaxel | Taxus brevifolia | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [15] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | SLC2A1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | ||
LN-229 | CVCL_0393 | Glioblastoma | Homo sapiens | |||
Experimental
Result(s) |
A combination of TMZ and Taxol exerted synergistic inhibitory effects on Taxol resistant glioma cells. | |||||
Piperine | Piper nigrum | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [16] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CCNE1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CDK2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CDK4 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CDK6 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | ||
T98G | CVCL_0556 | Glioblastoma | Homo sapiens | |||
Experimental
Result(s) |
Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines. | |||||
Progesterone | Dioscorea alata | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [17] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
|
In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
U-118MG | CVCL_0633 | Glioma | Homo sapiens | |||
Experimental
Result(s) |
PROG enhances the cytotoxic effects of TMZ in GBM cells and reduces its toxic side effects in healthy primary cells. | |||||
Quercetin | Averrhoa carambola | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [18] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | TP53 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | SK-MEL-28 | CVCL_0526 | Cutaneous melanoma | Homo sapiens | ||
SK-MEL-5 | CVCL_0527 | Cutaneous melanoma | Homo sapiens | |||
DB-1 | Melanoma | Homo sapiens | ||||
Experimental
Result(s) |
Qct can sensitize cells to TMZ and that the mechanisms of sensitization involve modulation of p53 family members. | |||||
Resveratrol | Gnetum parvifolium | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [19] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | GFAP | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | PRKAA1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | SHG-44 | CVCL_6728 | Astrocytoma | Homo sapiens | ||
In-vivo Model | SHG44 cells (5*105 cells per mouse) in 5 uL of Hanks' solution were injected intracranially into the right caudate nucleus of 6- to 8-week-old female nude mice. | |||||
Experimental
Result(s) |
Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway. | |||||
Shikonin | Lithospermum erythrorhizon | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [20] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | MMP-2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | SNAI2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
In-vitro Model | U-118MG | CVCL_0633 | Glioma | Homo sapiens | ||
Experimental
Result(s) |
GBM-derived cells treated with a combination of SHK and TMZ showed decreases in their proliferation and migration capacities. These decreases were followed by the suppression of GMT through a reduction of beta3 integrin, MMP-2, MMP-9, Slug and vimentin expression via inactivation of PI3K/AKT signaling. | |||||
Thymoquinone | Nigella sativa | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [21] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BECN1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
Experimental
Result(s) |
TQ enhanced the anti-cancer activity of TMZ by inhibition of autophagy at the transcriptional level and decreased the colony-forming ability and NO production of U87MG cell line. | |||||
Triptolide | Tripterygium hypoglaucum | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [22] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | RELA | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
In-vitro Model | GIC-1 | Glioblastoma multiforme | Homo sapiens | |||
Experimental
Result(s) |
TPL sensitizes GICs to TMZ by synergistically enhancing apoptosis, which is likely resulting from the augmented repression of NF-KappaB signaling. | |||||
Vitamin D | Saccharomyces cerevisiae | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [23] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BECN1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | C6 | CVCL_0194 | Rat malignant glioma | Rattus norvegicus | ||
In-vivo Model | To establish the rat glioblastoma model, each rat was anesthetized. Following disinfection and incision of the skin with a scalpel, a hole was drilled through the skull 2-mm lateral and 2-mm anterior to the bregma, on the right side of the skull. | |||||
Experimental
Result(s) |
Combined use of TMZ and VD exerts synergistic antitumor effects on rat models of glioblastoma and may represent an effective therapeutic strategy. | |||||
β. A List of Natural Product(s) Able to Reverse the Resistance of This Drug | ||||||
Acteoside | Cistanche | Click to Show/Hide the Molecular Data of This NP | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [24] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CD107a | Molecule Info |
Pathway MAP
|
|
Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | p38 beta | Molecule Info |
Pathway MAP
|
||
In-vitro Model | C6 | CVCL_0194 | Rat malignant glioma | Rattus norvegicus | ||
Experimental
Result(s) |
Acteoside has beneficial effects on TMZ based glioblastoma therapy. | |||||
Cyclopamine | Veratrum californicum | Click to Show/Hide the Molecular Data of This NP | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [25] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
Experimental
Result(s) |
Combination of TMZ with micellarized Cyp is a promising strategy for exerting different functions of drugs for tumor treatment. | |||||
Sulforaphane | Brassica oleracea | Click to Show/Hide the Molecular Data of This NP | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [26] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | MGMT | Molecule Info | ||
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
U-373MG ATCC | CVCL_2219 | Astrocytoma | Homo sapiens | |||
T98G | CVCL_0556 | Glioblastoma | Homo sapiens | |||
In-vivo Model | Nude mouse models were established with U373-R GBM cells inoculated subcutaneously into the right flanks of 4-6-week-old female mice. | |||||
Experimental
Result(s) |
SFN effectively inhibited activity of NF-KappaB signaling pathway and then reduced MGMT expression to reverse the chemo-resistance to TMZ in T98G, U87-R and U373-R cell lines. | |||||
Ursolic acid | Potentilla indica | Click to Show/Hide the Molecular Data of This NP | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [27] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | MGMT | Molecule Info | ||
In-vitro Model | LN-229 | CVCL_0393 | Glioblastoma | Homo sapiens | ||
LN-18 | CVCL_0392 | Glioblastoma | Homo sapiens | |||
T98G | CVCL_0556 | Glioblastoma | Homo sapiens | |||
In-vivo Model | LN18 cells (5*106/mouse) were subcutaneously injected into the left hind flank of each female BALB/c mouse. | |||||
Experimental
Result(s) |
Ursolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expression. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Human Deoxyribonucleic acid (hDNA) | Molecule Info | [28] |